Press coverage about The Medicines (NASDAQ:MDCO) has been trending somewhat positive on Sunday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. The Medicines earned a news impact score of 0.06 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.6023785862302 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
A number of equities research analysts have weighed in on MDCO shares. Oppenheimer set a $50.00 price objective on shares of The Medicines and gave the stock a “buy” rating in a report on Monday, January 15th. Zacks Investment Research upgraded shares of The Medicines from a “sell” rating to a “buy” rating and set a $31.00 price objective on the stock in a report on Tuesday, January 2nd. Jefferies Group restated a “buy” rating and issued a $54.00 price objective on shares of The Medicines in a report on Thursday, October 26th. Guggenheim started coverage on shares of The Medicines in a report on Monday, October 23rd. They issued a “buy” rating and a $45.00 price objective on the stock. Finally, ValuEngine upgraded shares of The Medicines from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $52.56.
Shares of The Medicines (NASDAQ MDCO) opened at $24.83 on Friday. The firm has a market cap of $1,800.00, a PE ratio of -2.71 and a beta of 0.71. The company has a quick ratio of 1.79, a current ratio of 2.31 and a debt-to-equity ratio of 3.42. The Medicines has a fifty-two week low of $24.45 and a fifty-two week high of $55.95.
The Medicines (NASDAQ:MDCO) last announced its quarterly earnings data on Wednesday, October 25th. The company reported ($0.42) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.37) by $0.95. The Medicines had a negative net margin of 767.94% and a negative return on equity of 174.68%. The business had revenue of $16.87 million for the quarter, compared to analysts’ expectations of $26.06 million. During the same quarter in the prior year, the company earned ($0.64) earnings per share. The business’s revenue was down 55.1% compared to the same quarter last year. equities analysts expect that The Medicines will post -8.86 EPS for the current year.
In other news, CEO Clive Meanwell sold 136,250 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $27.24, for a total transaction of $3,711,450.00. Following the sale, the chief executive officer now owns 587,652 shares in the company, valued at $16,007,640.48. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Fredric N. Eshelman purchased 200,000 shares of the business’s stock in a transaction dated Friday, December 8th. The shares were purchased at an average price of $26.56 per share, for a total transaction of $5,312,000.00. Following the acquisition, the insider now owns 1,028,383 shares of the company’s stock, valued at $27,313,852.48. The disclosure for this purchase can be found here. Corporate insiders own 8.22% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/21/the-medicines-mdco-getting-somewhat-positive-press-coverage-study-shows.html.
The Medicines Company Profile
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.